Target Information

Target General Information

Top

Target ID

T66693 (Former ID: TTDR00934)

Target Name

B-cell maturation protein (TNFRSF17)

Synonyms

Tumor necrosis factor receptor superfamily member 17; CD269; BCMA; BCM

Click to Show/Hide

Gene Name

TNFRSF17

Target Type

Successful target

[1]

Disease

[+] 1 Target-related Diseases

Multiple myeloma [ICD-11: 2A83]

Function

Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL.

Click to Show/Hide

UniProt ID

TNR17_HUMAN

Sequence

MLQMAGQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGTNAILWTCL
GLSLIISLAVFVLMFLLRKINSEPLKDEFKNTGSGLLGMANIDLEKSRTGDEIILPRGLE
YTVEECTCEDCIKSKPKVDSDHCFPLPAMEEGATILVTTKTNDYCKSLPAALSATEIEKS
ISAR

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

AlphaFold

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 4 Approved Drugs

Belantamab mafodotin

Drug Info

Approved

Multiple myeloma

[2]

Elranatamab

Drug Info

Approved

Multiple myeloma

[3]

Idecabtagene vicleucel

Drug Info

Approved

Multiple myeloma

[4]

Teclistamab

Drug Info

Approved

Multiple myeloma

[5]

Clinical Trial Drug(s)

[+] 63 Clinical Trial Drugs

Ciltacabtagene autoleucel

Drug Info

Phase 3

Multiple myeloma

[6]

Bb2121

Drug Info

Phase 2

Multiple myeloma

[7], [8]

Descartes-08

Drug Info

Phase 2

Multiple myeloma

[9]

Descartes-11

Drug Info

Phase 2

Multiple myeloma

[10]

LCAR-B38M CAR-T Cell

Drug Info

Phase 2

Multiple myeloma

[1], [11]

Anti-BCMA CAR-T cells

Drug Info

Phase 1/2

Multiple myeloma

[12]

Anti-BCMA-CAR-transduced T cells

Drug Info

Phase 1/2

leukaemia

[13]

AUTO2

Drug Info

Phase 1/2

Multiple myeloma

[14]

BCMA CAR T cells

Drug Info

Phase 1/2

Multiple myeloma

[15]

BCMA CAR-T

Drug Info

Phase 1/2

Multiple myeloma

[16]

CAR-T cells targeting BCMA

Drug Info

Phase 1/2

leukaemia

[17]

CART-19/BCMA

Drug Info

Phase 1/2

Multiple myeloma

[18]

CART-BCMA cells

Drug Info

Phase 1/2

Multiple myeloma

[19]

CD38 and BCMA CAR-T Cells

Drug Info

Phase 1/2

Multiple myeloma

[20]

JCARH125

Drug Info

Phase 1/2

Multiple myeloma

[21], [22]

JNJ-68284528

Drug Info

Phase 1/2

Multiple myeloma

[23]

PBCAR269A

Drug Info

Phase 1/2

Multiple myeloma

[24]

REGN5458

Drug Info

Phase 1/2

Multiple myeloma

[25]

REGN5459

Drug Info

Phase 1/2

Multiple myeloma

[26]

ALLO-715

Drug Info

Phase 1

Multiple myeloma

[27]

AMG 420

Drug Info

Phase 1

Multiple myeloma

[7], [8]

AMG 701

Drug Info

Phase 1

Multiple myeloma

[7]

Anti-BCMA CAR T cells

Drug Info

Phase 1

Multiple myeloma

[28]

Anti-BCMA CAR T cells

Drug Info

Phase 1

Multiple myeloma

[29], [30]

Anti-BCMA CAR-T cells

Drug Info

Phase 1

Multiple myeloma

[31]

Anti-BCMA CAR-T cells

Drug Info

Phase 1

leukaemia

[32]

Anti-BCMA CART Cells

Drug Info

Phase 1

Multiple myeloma

[33]

Anti-CD19/BCMA CAR-T cells

Drug Info

Phase 1

Multiple myeloma

[34]

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143

Drug Info

Phase 1

Plasma cell myeloma

[35]

Bb21217

Drug Info

Phase 1

Multiple myeloma

[36]

BCMA CAR-T Cells

Drug Info

Phase 1

Multiple myeloma

[37]

BCMA CART

Drug Info

Phase 1

Multiple myeloma

[38]

BCMA CART and huCART19

Drug Info

Phase 1

Multiple myeloma

[38]

BCMA nanobody CAR-T cells

Drug Info

Phase 1

Multiple myeloma

[39]

BCMA-CD19 cCAR

Drug Info

Phase 1

Multiple myeloma

[40]

BCMA-CS1 cCAR

Drug Info

Phase 1

Multiple myeloma

[41]

BCMA-specific CAR-expressing T Lymphocytes

Drug Info

Phase 1

Plasma cell myeloma

[42]

C-CAR088

Drug Info

Phase 1

Multiple myeloma

[43]

CAR-T cells targeting BCMA

Drug Info

Phase 1

Multiple myeloma

[44]

CART-BCMA

Drug Info

Phase 1

Multiple myeloma

[45]

CART-ddBCMA

Drug Info

Phase 1

Multiple myeloma

[46]

CC-93269

Drug Info

Phase 1

Multiple myeloma

[7]

CC-98633

Drug Info

Phase 1

Multiple myeloma

[47]

CC-99712

Drug Info

Phase 1

Multiple myeloma

[48]

CT053

Drug Info

Phase 1

Multiple myeloma

[49]

CTX120

Drug Info

Phase 1

Multiple myeloma

[50]

HPN217

Drug Info

Phase 1

Multiple myeloma

[51]

IM21 CART

Drug Info

Phase 1

Multiple myeloma

[52]

KITE-585

Drug Info

Phase 1

Multiple myeloma

[7]

LCAR-B4822M CAR-T Cell

Drug Info

Phase 1

Multiple myeloma

[53]

MEDI2228

Drug Info

Phase 1

Multiple myeloma

[54]

P-BCMA-101 CAR-T cells

Drug Info

Phase 1

Multiple myeloma

[55]

P-PSMA-101

Drug Info

Phase 1

Prostate cancer

[56]

PHE885

Drug Info

Phase 1

Multiple myeloma

[57]

RG6296

Drug Info

Phase 1

Multiple myeloma

[58]

RG6538

Drug Info

Phase 1

Multiple myeloma

[59]

SEA-BCMA

Drug Info

Phase 1

Multiple myeloma

[60]

TNB-383B

Drug Info

Phase 1

Multiple myeloma

[61]

WVT078

Drug Info

Phase 1

Multiple myeloma

[62]

BCMA-CART

Drug Info

Clinical trial

Multiple myeloma

[63]

BCMA-UCART

Drug Info

Clinical trial

Multiple myeloma

[64]

CAR-BCMA T cell

Drug Info

Clinical trial

Multiple myeloma

[65]

CAR-T cells targeting BCMA

Drug Info

Clinical trial

Multiple myeloma

[66]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

P-BCMA-ALL01

Drug Info

Preclinical

Multiple myeloma

[67]

Mode of Action

[+] 4 Modes of Action

CAR-T-Cell-Therapy

[+] 33 CAR-T-Cell-Therapy drugs

Idecabtagene vicleucel

Drug Info

[4]

Descartes-08

Drug Info

[68]

LCAR-B38M CAR-T Cell

Drug Info

[1], [11]

Anti-BCMA CAR-T cells

Drug Info

[12]

Anti-BCMA-CAR-transduced T cells

Drug Info

[13]

BCMA CAR T cells

Drug Info

[15]

BCMA CAR-T

Drug Info

[16]

CAR-T cells targeting BCMA

Drug Info

[17]

CART-BCMA cells

Drug Info

[19]

JCARH125

Drug Info

[21], [22]

JNJ-68284528

Drug Info

[23]

Anti-BCMA CAR T cells

Drug Info

[28]

Anti-BCMA CAR T cells

Drug Info

[29], [30]

Anti-BCMA CAR-T cells

Drug Info

[31]

Anti-BCMA CAR-T cells

Drug Info

[32]

Anti-BCMA CART Cells

Drug Info

[33]

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143

Drug Info

[35]

Bb21217

Drug Info

[36]

BCMA CAR-T Cells

Drug Info

[37]

BCMA CART

Drug Info

[38]

BCMA nanobody CAR-T cells

Drug Info

[39]

BCMA-specific CAR-expressing T Lymphocytes

Drug Info

[42]

C-CAR088

Drug Info

[43]

CAR-T cells targeting BCMA

Drug Info

[44]

CART-BCMA

Drug Info

[45]

IM21 CART

Drug Info

[52]

KITE-585

Drug Info

[80]

LCAR-B4822M CAR-T Cell

Drug Info

[53]

P-BCMA-101 CAR-T cells

Drug Info

[55]

BCMA-CART

Drug Info

[63]

BCMA-UCART

Drug Info

[64]

CAR-BCMA T cell

Drug Info

[65]

CAR-T cells targeting BCMA

Drug Info

[66]

Immunomodulator

[+] 1 Immunomodulator drugs

Bb2121

Drug Info

[8]

CAR-T-Cell-Therapy(Dual specific)

[+] 5 CAR-T-Cell-Therapy(Dual specific) drugs

AUTO2

Drug Info

[14]

CART-19/BCMA

Drug Info

[18]

CD38 and BCMA CAR-T Cells

Drug Info

[20]

Anti-CD19/BCMA CAR-T cells

Drug Info

[34]

BCMA CART and huCART19

Drug Info

[38]

Inhibitor

[+] 6 Inhibitor drugs

REGN5458

Drug Info

[71]

REGN5459

Drug Info

[72]

AMG 420

Drug Info

[74]

AMG 701

Drug Info

[75]

MEDI2228

Drug Info

[81]

RG6296

Drug Info

[83]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function. Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006). Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database. The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017). Human Similarity Proteins Human Pathway Affiliation Biological Network Descriptors

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.

Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006).

Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.

The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017).

Human Similarity Proteins

Human Pathway Affiliation

Biological Network Descriptors

There is no similarity protein (E value < 0.005) for this target

KEGG Pathway	Pathway ID	Affiliated Target
Cytokine-cytokine receptor interaction	hsa04060	Affiliated Target
Class: Environmental Information Processing => Signaling molecules and interaction	Pathway Hierarchy
Intestinal immune network for IgA production	hsa04672	Affiliated Target
Class: Organismal Systems => Immune system	Pathway Hierarchy

Degree	5	Degree centrality	5.37E-04	Betweenness centrality	1.75E-05
Closeness centrality	1.89E-01	Radiality	1.32E+01	Clustering coefficient	6.00E-01
Neighborhood connectivity	1.20E+01	Topological coefficient	2.61E-01	Eccentricity	12
Download	Click to Download the Full PPI Network of This Target

Target Regulators

Top

Target-interacting Proteins

Target-interacting Proteins Info

References

Top

REF 1

ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020

REF 3

FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345

REF 4

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.

REF 5

FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.

REF 6

ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.

REF 7

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 8

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 9

ClinicalTrials.gov (NCT04816526) Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health.

REF 10

ClinicalTrials.gov (NCT04436029) Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health.

REF 11

ClinicalTrials.gov (NCT03090659) LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

REF 12

ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

REF 13

ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

REF 14

ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

REF 15

ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

REF 16

ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma

REF 17

ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

REF 18

ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

REF 19

ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma

REF 20

ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

REF 21

ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

REF 22

ClinicalTrials.gov (NCT03430011) Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

REF 23

ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

REF 24

ClinicalTrials.gov (NCT04171843) A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 25

ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 26

ClinicalTrials.gov (NCT04083534) First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM). U.S. National Institutes of Health.

REF 27

ClinicalTrials.gov (NCT04093596) Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). U.S. National Institutes of Health.

REF 28

ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma

REF 29

ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

REF 30

ClinicalTrials.gov (NCT03602612) T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

REF 31

ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

REF 32

ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

REF 33

ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

REF 34

ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

REF 35

ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

REF 36

ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma

REF 37

ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

REF 38

ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

REF 39

ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

REF 40

ClinicalTrials.gov (NCT04162353) BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma. U.S. National Institutes of Health.

REF 41

ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 42

ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma

REF 43

ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma

REF 44

ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

REF 45

ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma

REF 46

Clinical pipeline report, company report or official report of Arcellx.

REF 47

ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 48

ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 49

ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health.

REF 50

ClinicalTrials.gov (NCT04244656) A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 51

ClinicalTrials.gov (NCT04184050) A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM. U.S. National Institutes of Health.

REF 52

ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

REF 53

ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

REF 54

ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health.

REF 55

ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

REF 56

ClinicalTrials.gov (NCT04249947) P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.

REF 57

ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 58

ClinicalTrials.gov (NCT04434469) A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 59

Clinical pipeline report, company report or official report of Roche

REF 60

ClinicalTrials.gov (NCT03582033) A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.

REF 61

ClinicalTrials.gov (NCT03933735) A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.

REF 62

ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.

REF 63

ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma

REF 64

ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART

REF 65

ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

REF 66

ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma

REF 67

Clinical pipeline report, company report or official report of Poseida Therapeutics.

REF 68

ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

REF 69

Clinical pipeline report, company report or official report of Cartesian Therapeutics.

REF 70

Clinical pipeline report, company report or official report of Precision Biosciences.

REF 71

A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.

REF 72

Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.

REF 73

Clinical pipeline report, company report or official report of Allogene Therapeutics.

REF 74

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783.

REF 75

Clinical pipeline report, company report or official report of Amgen.

REF 76

Clinical pipeline report, company report or official report of iCell Gene Therapeutics.

REF 77

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020 Nov 10;11(45):4076-4081.

REF 78

Clinical pipeline report, company report or official report of CRISPR Therapeutics.

REF 79

Clinical pipeline report, company report or official report of AbbVie.

REF 80

ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

REF 81

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.

REF 82

Clinical pipeline report, company report or official report of Poseida Therapeutics.

REF 83

Clinical pipeline report, company report or official report of Genentech.

REF 84

Clinical pipeline report, company report or official report of AbbVie.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN